Stock Price & Analysis

Based on recent data, selling NBIX stock appears prudent as the company's shares tumbled 19.23% after missing Q4 revenue estimates, with multiple analysts lowering price targets despite maintaining positive ratings.

The technical indicators show concerning signals with RSI at 24.16 and MACD at -0.55, suggesting bearish momentum and oversold conditions that could persist in the near term.

Based on recent earnings reports and analyst updates, NBIX stock is projected to reach $165-175 by end of 2025, driven by expected Ingrezza sales of $2.5-2.6 billion and potential growth from newly launched Crenessity. However, near-term competitive pressures and payer dynamics have led multiple analysts to lower their price targets, with recent cuts from UBS ($154), Guggenheim ($163), and HC Wainwright ($185). The stock is currently showing technical weakness after falling below its 200-day moving average, with support around $110-115 range.

{RATING:symbol=NBIX,type=0}

The S1 support level for NBIX Stock is $121.67 ,The R1 resistant level for NBIX Stock is $152.3.

As of the end of day on 2025-02-11, the price of NBIX Stock was $117.24.

The target price for NBIX Stock according to analyst rating is 170.61, with the highest price target at 192.00 and the lowest at 145.00. Analysts have a Strong Buy rating on NBIX Stock overall.

The market cap of NBIX is $11.8B.

Based on the recent data and market movements, NBIX appears to be fairly valued with some near-term headwinds. Here's why:

Recent Performance The stock has experienced significant downward pressure, falling 19.23% last week after missing Q4 revenue estimates, despite beating EPS expectations.

Valuation Metrics The stock's current valuation metrics show:

• P/E: 41.47x (Q4 2024)
• EV/EBITDA: 21.86x
• P/S: 6.01x
• P/B: 5.34x

Growth & Fundamentals

• Revenue grew 21.8% YoY to $627.7M in Q4 2024
• Net margin improved to 16.43% in Q4 2024
• Strong balance sheet with current ratio of 3.40x
• Zero debt-to-equity ratio as of Q4 2024

Market Position Ingrezza remains the gold-standard treatment for tardive dyskinesia with 14 years of patent protection remaining. However, management's 2025 Ingrezza revenue guidance of $2.5-2.6B came in below Street estimates of $2.67B, indicating some near-term competitive pressures.

Technical Indicators

• RSI at 24.16 indicates oversold conditions
• Trading below both 20-day SMA ($144.98) and Fibonacci support level ($123.87)
• MACD showing bearish momentum (-0.55)

The stock appears fairly valued considering its strong market position and growth prospects, balanced against near-term competitive pressures and conservative guidance. The recent selloff has created an oversold condition, but caution is warranted until competitive dynamics become clearer.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Based on recent earnings reports and analyst forecasts, NBIX stock is projected to reach $185-190 by 2030, driven by continued growth of Ingrezza sales expected to exceed $3.5 billion annually and potential success of Crenessity as a second blockbuster therapy. The company's strong patent protection for Ingrezza extending through 2039 and expanding sales force provide solid growth foundation. However, near-term competitive pressures and payer utilization management could moderate growth trajectory, as reflected in conservative 2025 guidance of $2.5-2.6 billion for Ingrezza sales.

NBIX has a total of 1400 employees.